What Can We Expect From Boston Scientific’s Q2’16 Earnings?

Boston Scientific  (NYSE:BSX) is set to report its Q2 2016 earnings on July 28th. The company’s Q1 2016 results surpassed investor expectations as most of the key financial metrics came in above the company’s guided range and the expected consensus estimates for the quarter. Furthermore, Boston Scientific saw outstanding growth across all the regions of the operation. Moreover, the company raised its full year revenue guidance for 2016 by $15 million at the midpoint. The stock has gained by more than 20 percent since then, as investors took note of the company’s strong growth prospects going ahead.

In Q2, Boston Scientific’s operating margins likely declined sequentially due to higher SG&A expenses incurred, driven by increased trade show activities around this time of the year. The company expects its adjusted operating margins to decline by around 160 basis points in Q2. Nevertheless, Boston Scientific expects a 200 basis points improvement in its adjusted operating margins for 2016. Furthermore, we can expect the company to report strong revenue growth in the Interventional Cardiology and MedSurg segments, driven by an increase in drug-eluting stent sales, led by Synergy DES sales. Below we look at the key metrics as expected for Boston Scientific’s Q2’16 results:

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology